Science & Technology
Wed, August 13, 2025
[ Yesterday Afternoon ]: gizmodo.com
[ Yesterday Afternoon ]: Sports Illustrated
[ Yesterday Afternoon ]: HELLO BEAUTIFUL
[ Yesterday Afternoon ]: St. Louis Post-Dispatch
[ Yesterday Afternoon ]: Business Insider
[ Yesterday Morning ]: Associated Press Finance
[ Yesterday Morning ]: Forbes
[ Yesterday Morning ]: Ghanaweb.com
[ Yesterday Morning ]: Impacts
[ Yesterday Morning ]: Wyoming News
[ Yesterday Morning ]: dpa international
[ Yesterday Morning ]: Mental Floss
[ Yesterday Morning ]: Seeking Alpha
[ Yesterday Morning ]: The Motley Fool
[ Yesterday Morning ]: The Boston Globe
[ Yesterday Morning ]: The Daily News Online
[ Yesterday Morning ]: WOFL
[ Yesterday Morning ]: BBC
[ Yesterday Morning ]: ScienceAlert
[ Yesterday Morning ]: KHON Honolulu
Tue, August 12, 2025
[ Last Tuesday ]: breitbart.com
[ Last Tuesday ]: USA TODAY
[ Last Tuesday ]: Valley News Live
[ Last Tuesday ]: Defense News
[ Last Tuesday ]: KCCI Des Moines
[ Last Tuesday ]: WAVE3
[ Last Tuesday ]: Men's Fitness
[ Last Tuesday ]: Slate
[ Last Tuesday ]: Penn Live
[ Last Tuesday ]: 14 NEWS
[ Last Tuesday ]: SB Nation
[ Last Tuesday ]: WGN Chicago
[ Last Tuesday ]: The Straits Times
[ Last Tuesday ]: The Motley Fool
[ Last Tuesday ]: WPTV-TV
[ Last Tuesday ]: yahoo.com
[ Last Tuesday ]: Ghanaweb.com
[ Last Tuesday ]: WKBN 27 First News
[ Last Tuesday ]: The Scotsman
[ Last Tuesday ]: Forbes
[ Last Tuesday ]: Reuters
[ Last Tuesday ]: The News-Gazette
[ Last Tuesday ]: STAT
[ Last Tuesday ]: Sports Illustrated
[ Last Tuesday ]: moneycontrol.com
[ Last Tuesday ]: HuffPost
[ Last Tuesday ]: Time
[ Last Tuesday ]: The Oklahoman
[ Last Tuesday ]: Food & Wine
[ Last Tuesday ]: Lowyat.net
Mon, August 11, 2025
[ Last Monday ]: Futurism
[ Last Monday ]: Tasting Table
[ Last Monday ]: USA TODAY
[ Last Monday ]: WAFF
[ Last Monday ]: The Motley Fool
[ Last Monday ]: Seeking Alpha
[ Last Monday ]: TechCrunch
[ Last Monday ]: WSMV
[ Last Monday ]: Tampa Free Press
[ Last Monday ]: WHIO
[ Last Monday ]: Business Insider
[ Last Monday ]: New Hampshire Union Leader
[ Last Monday ]: ABC Kcrg 9
[ Last Monday ]: breitbart.com
[ Last Monday ]: The Financial Express
[ Last Monday ]: newsbytesapp.com
[ Last Monday ]: SB Nation
[ Last Monday ]: reuters.com
[ Last Monday ]: SB Nation
[ Last Monday ]: ESPN
[ Last Monday ]: Chattanooga Times Free Press
[ Last Monday ]: BBC
[ Last Monday ]: Ghanaweb.com
[ Last Monday ]: Reuters
[ Last Monday ]: Live Science
[ Last Monday ]: newsbytesapp.com
[ Last Monday ]: Impacts
[ Last Monday ]: The West Australian
Sun, August 10, 2025
[ Last Sunday ]: Fox News
[ Last Sunday ]: The Cool Down
[ Last Sunday ]: Seeking Alpha
[ Last Sunday ]: Real Simple
[ Last Sunday ]: Vogue
[ Last Sunday ]: The Conversation
[ Last Sunday ]: The Takeout
[ Last Sunday ]: earth
[ Last Sunday ]: newsbytesapp.com
[ Last Sunday ]: Seattle Times
[ Last Sunday ]: Press-Republican, Plattsburgh, N.Y.
[ Last Sunday ]: Las Vegas Review-Journal
[ Last Sunday ]: LA Times
[ Last Sunday ]: indulgexpress
[ Last Sunday ]: The Motley Fool
Sat, August 9, 2025
[ Last Saturday ]: Killeen Daily Herald
[ Last Saturday ]: ThePrint
[ Last Saturday ]: TV Technology
[ Last Saturday ]: The Motley Fool
[ Last Saturday ]: WTAE-TV
[ Last Saturday ]: WSAV Savannah
[ Last Saturday ]: The West Australian
[ Last Saturday ]: Sports Illustrated
[ Last Saturday ]: Chowhound
[ Last Saturday ]: Local 12 WKRC Cincinnati
[ Last Saturday ]: uDiscover
[ Last Saturday ]: WRBL Columbus
[ Last Saturday ]: Telangana Today
[ Last Saturday ]: Forbes
[ Last Saturday ]: The Cool Down
[ Last Saturday ]: The Straits Times
[ Last Saturday ]: moneycontrol.com
[ Last Saturday ]: BBC
[ Last Saturday ]: Ghanaweb.com
[ Last Saturday ]: Seeking Alpha
Fri, August 8, 2025
[ Last Friday ]: sportskeeda.com
[ Last Friday ]: The Motley Fool
[ Last Friday ]: WBTW Myrtle Beach
[ Last Friday ]: Ghanaweb.com
[ Last Friday ]: WVLA Baton Rouge
[ Last Friday ]: Los Angeles Times Opinion
[ Last Friday ]: Democrat and Chronicle
[ Last Friday ]: Patch
[ Last Friday ]: TechRadar
[ Last Friday ]: WNCT Greenville
[ Last Friday ]: The Tennessean
[ Last Friday ]: The Greenville News
[ Last Friday ]: The Conversation
Wed, August 6, 2025
[ Wed, Aug 06th ]: HELLO! Magazine
[ Wed, Aug 06th ]: United Press International
[ Wed, Aug 06th ]: Bring Me the News
[ Wed, Aug 06th ]: WAVY
[ Wed, Aug 06th ]: Los Angeles Times
[ Wed, Aug 06th ]: news4sanantonio
[ Wed, Aug 06th ]: News 8000
[ Wed, Aug 06th ]: San Francisco Examiner
[ Wed, Aug 06th ]: The Atlantic
[ Wed, Aug 06th ]: TheBlast
[ Wed, Aug 06th ]: The Motley Fool
[ Wed, Aug 06th ]: Ghanaweb.com
[ Wed, Aug 06th ]: Yen.com.gh
[ Wed, Aug 06th ]: CoinTelegraph
[ Wed, Aug 06th ]: Sports Illustrated
[ Wed, Aug 06th ]: The Financial Express
[ Wed, Aug 06th ]: KHQ
[ Wed, Aug 06th ]: gulfcoastnewsnow.com
[ Wed, Aug 06th ]: Seeking Alpha
[ Wed, Aug 06th ]: Space.com
[ Wed, Aug 06th ]: WBAY
[ Wed, Aug 06th ]: WLOX
[ Wed, Aug 06th ]: HuffPost
[ Wed, Aug 06th ]: SlashGear
[ Wed, Aug 06th ]: NorthJersey.com
[ Wed, Aug 06th ]: DW
[ Wed, Aug 06th ]: BGR
[ Wed, Aug 06th ]: Business Today
[ Wed, Aug 06th ]: Forbes
[ Wed, Aug 06th ]: STAT
Tue, August 5, 2025
[ Tue, Aug 05th ]: People
[ Tue, Aug 05th ]: Impacts
[ Tue, Aug 05th ]: Washington Post
[ Tue, Aug 05th ]: The Independent
[ Tue, Aug 05th ]: fingerlakes1
[ Tue, Aug 05th ]: Chowhound
[ Tue, Aug 05th ]: UPI
[ Tue, Aug 05th ]: Fortune
[ Tue, Aug 05th ]: Indiana Capital Chronicle
[ Tue, Aug 05th ]: Local 12 WKRC Cincinnati
[ Tue, Aug 05th ]: The Clarion-Ledger
[ Tue, Aug 05th ]: LA Times
[ Tue, Aug 05th ]: moneycontrol.com
[ Tue, Aug 05th ]: Seeking Alpha
[ Tue, Aug 05th ]: WJAX
[ Tue, Aug 05th ]: USA TODAY
[ Tue, Aug 05th ]: Forbes
Mon, August 4, 2025
[ Mon, Aug 04th ]: Parade
[ Mon, Aug 04th ]: HELLO! Magazine
[ Mon, Aug 04th ]: The Motley Fool
[ Mon, Aug 04th ]: Associated Press
[ Mon, Aug 04th ]: People
[ Mon, Aug 04th ]: sportskeeda.com
[ Mon, Aug 04th ]: Impacts
[ Mon, Aug 04th ]: ThePrint
[ Mon, Aug 04th ]: New Hampshire Bulletin
Gilead Sciences Q2 Preview: What to expect
//science-technology.news-articles.net/content/2 .. 6/gilead-sciences-q2-preview-what-to-expect.html
Published in Science and Technology on Wednesday, August 6th 2025 at 13:07 GMT by Seeking Alpha🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
Gilead Sciences (GILD) Q2 earnings preview: Analysts expect a $1.96 EPS and $6.96B revenue.
Gilead Sciences Q2 Earnings Preview: Navigating Growth Amidst Challenges
As Gilead Sciences (GILD) gears up to report its second-quarter financial results, investors and analysts are keenly focused on how the biopharmaceutical giant is positioning itself in a competitive landscape marked by robust HIV treatments, expanding oncology portfolios, and lingering impacts from its COVID-19 therapies. The earnings release, expected after market close, followed by a conference call, comes at a pivotal time for the company, which has been striving to diversify beyond its core antiviral franchise while contending with patent cliffs and market dynamics. Wall Street's consensus points to a mixed outlook, with expectations of steady revenue growth driven by key products, but tempered by potential headwinds in certain segments.
At the heart of Gilead's Q2 narrative is its HIV business, which remains the company's revenue powerhouse. Drugs like Biktarvy, a once-daily single-tablet regimen for HIV treatment, are anticipated to continue their strong performance. In the first quarter, Biktarvy generated over $2.6 billion in sales, representing a significant portion of Gilead's total product sales. Analysts project that this momentum will persist into Q2, bolstered by increasing market share in the U.S. and international expansions. The HIV segment as a whole is expected to contribute around $4.5 billion to $4.7 billion in revenue, reflecting Gilead's dominance in this area despite growing competition from rivals like ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. Factors such as patient adherence programs and pricing strategies will be closely watched, as any shifts could influence long-term growth trajectories.
Beyond HIV, Gilead's oncology division is emerging as a key growth driver, particularly with Trodelvy, its antibody-drug conjugate approved for certain breast and urothelial cancers. Acquired through the $21 billion Immunomedics deal in 2020, Trodelvy has shown promising uptake, with Q1 sales reaching approximately $200 million. For Q2, expectations hover around $250 million to $300 million, fueled by label expansions and real-world evidence supporting its efficacy. Gilead's broader oncology pipeline, including magrolimab for blood cancers and other investigational therapies, could provide updates during the earnings call, potentially signaling future revenue streams. However, challenges such as clinical trial setbacks or regulatory hurdles might temper enthusiasm, as the company works to build a more diversified portfolio amid declining revenues from older hepatitis C treatments.
The remnants of Gilead's COVID-19 efforts, primarily through Veklury (remdesivir), add another layer to the Q2 preview. While demand for the antiviral has waned with the pandemic's evolution, it still contributed about $500 million in Q1 sales. Analysts forecast a further decline to $300 million to $400 million in Q2, reflecting reduced hospitalizations and the availability of alternative treatments. This segment's performance underscores Gilead's adaptability during global health crises but also highlights the volatility of relying on emergency-use authorizations. Investors will be eager for commentary on any residual inventory or potential repurposing of Veklury for other indications.
Financially, consensus estimates from analysts peg Q2 revenue at around $6.6 billion, marking a slight increase from the $6.3 billion reported in the same quarter last year. This growth is attributed to the aforementioned strengths in HIV and oncology, offsetting declines in other areas like cell therapy products such as Yescarta and Tecartus, which face manufacturing and reimbursement challenges. Earnings per share (EPS) are projected at $1.60 to $1.70 on a non-GAAP basis, compared to $1.58 in Q2 of the previous year. Gilead's management has guided for full-year revenue between $26 billion and $26.5 billion, and any reaffirmation or adjustment to this outlook will be critical. The company's strong cash position, exceeding $7 billion as of Q1, provides flexibility for strategic moves, including bolt-on acquisitions or share buybacks, which totaled $1.5 billion in the first half of the year.
Stock performance leading into earnings has been lackluster, with GILD shares trading in a narrow range amid broader market volatility. Year-to-date, the stock has underperformed the S&P 500, reflecting investor concerns over patent expirations for key drugs like Truvada and potential biosimilar competition. Analyst sentiment is mixed: while some firms like Jefferies and RBC Capital maintain Buy ratings with price targets around $80 to $90, others express caution due to limited near-term catalysts. The average price target sits at approximately $75, implying modest upside from current levels around $65.
Looking ahead, several factors could sway the post-earnings reaction. Pipeline updates, particularly on lenacapavir, Gilead's investigational long-acting HIV prevention drug, could excite investors if positive data from ongoing trials is shared. Lenacapavir's potential as a twice-yearly injection represents a paradigm shift in HIV management and could open new revenue avenues. Additionally, Gilead's ventures into inflammation and fibrosis, through partnerships or internal developments, might offer glimpses into long-term diversification strategies. On the flip side, macroeconomic pressures such as inflation impacting R&D costs or supply chain disruptions could pose risks.
Gilead's Q2 results will also be viewed through the lens of its capital allocation priorities. The company has been aggressive in returning value to shareholders via dividends—yielding about 4.5%—and repurchases, but balancing this with investments in high-growth areas like oncology and virology remains key. CEO Daniel O'Day's commentary during the call will likely address these themes, emphasizing sustainable growth amid a maturing portfolio.
In summary, Gilead Sciences' Q2 earnings preview paints a picture of a company leveraging its established strengths in HIV while pushing into oncology and beyond. While revenue and EPS estimates suggest stability, the real story lies in forward-looking guidance and pipeline progress. Investors should monitor for any surprises in product sales, particularly Biktarvy and Trodelvy, as well as insights into competitive dynamics and innovation efforts. As the biopharma sector evolves, Gilead's ability to navigate these waters will determine its trajectory, making this earnings report a must-watch for those tracking healthcare investments. With a market cap exceeding $80 billion, the outcomes could influence broader sentiment in the biotech space, highlighting the interplay between established revenues and emerging opportunities. (Word count: 852)
Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/news/4480102-gilead-sciences-q2-preview-what-to-expect ]